Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
AZ’s STORM CHASER Falls Short On Ambitious COVID Symptom Goal
AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.
Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result
Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.
Vertex Urged To Target Major M&A After Another Rare Disease Failure
After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.
Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It
The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.
Bayer Advances Parkinson’s Cell And Gene Therapies Into First Human Studies
As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.
Novartis Challenger To Alexion Advances In Rare Kidney Disease
First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.